市场调查报告书
商品编码
1439252
化学品注入系统 - 全球市场考量、竞争格局、市场预测 (2030)Drug Infusion System - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
全球药物注射系统市场规模预计到2023年将达到117.3亿美元,到2030年将达到194.5亿美元,2024-2030年预测期间复合年增长率为8.85%。药物注射系统的需求主要是由癌症和糖尿病等慢性病盛行率上升、老年人口不断增加以及产品开发技术进步所推动的。
药物注射系统的市场动态
由于各种癌症等慢性疾病的盛行率不断上升,预计药物注射系统市场将在预测期内显着增长。例如,根据世界卫生组织(WHO)引用的数据(2022年),大约有226万例乳腺癌、221万例肺癌、193万例结直肠癌和141万例前列腺癌。到2020 年,全球将有109 万例胃癌病例。
根据国际糖尿病联盟(IDF)(2023)发布的统计数据,2021年全球有5.37亿成年人患有糖尿病。预计到 2030 年,这一数字将增至 6.43 亿,到 2045 年将增至 7.83 亿。
上述事实是世界各地癌症和慢性病数量迅速增加的一个例子。慢性病通常会影响个体的一生,需要长期的治疗介入。为此使用化学注射系统。药物输送系统是一种向患者输送抗生素、止痛药、荷尔蒙和化疗等药物和营养物质的医疗设备。这些系统有多种配置,包括固定式和移动式。这些设备可提供安全、准确的药物输送,无需持续确认剂量。
此外,技术的进步促进了可程式药物输注系统的发展,该系统提供流速和警报等功能,可轻鬆追踪剂量。例如,B. Braun Melsugen AG 的 Space ecosystem是一个由 OnlineSuiteplus 支援的整合输液系统。此整合系统提供连接和资料管理、标准化互通性、卓越护理和基于云端的应用程式等功能。
然而,除了产品召回之外,与输液系统相关的技术问题(例如断开和校准问题)可能会对药物输液系统市场的成长产生一定的限制。
药物注射系统市场细分分析
据估计,基于注射器的注射系统将在药物注射系统市场的产品领域中占据主要份额。
这是因为产品设计简单,应用范围广泛。
注射帮浦广泛应用于临床环境。因此,将注射器连接到系统并根据您的要求对药物输送进行编程。
当需要少量药物时,这些系统非常有用。
注射器注射系统特别适合对婴儿、新生儿和幼儿等年轻患者进行给药。
因此,注射器注射系统所提供的优势将在预测期内增加其需求。
预计北美将主导整个药物注射系统市场。
在所有地区中,预计北美将占据药物注射系统市场的最大份额。慢性背痛、糖尿病和癌症等慢性病的盛行率、完善的医疗保健系统、主要市场参与者的存在等预计将成为预测期内推动整体药物注射系统市场增长的关键影响因素。 。
美国疾病管制与预防中心(CDC)提供的资讯显示,根据National Health Survey 2019,到2019年,大约20.4%的成年人将患有慢性疼痛,7.4%的成年人会经常限制他们的工作或生活活动。患有慢性疼痛(被认为是高负担慢性疼痛)。研究认为,高负担慢性疼痛和慢性疼痛在 65 岁以上的人群中更为普遍,并且随着年龄的增长而恶化。
该报告提供了全球药物注射系统市场的研究和分析,包括市场规模和预测、驱动因素和挑战以及公司和产品概况。
Drug Infusion Systems Market By Product Type (Syringe Infusion Systems, Elastomeric Infusion Systems, Large Volume Infusion Systems, Enteral Infusion Systems, Patient-Controlled Analgesic Infusion Systems, Insulin Pumps, and Others), Product Placement (External and Implantable), Portability (Fixed and Ambulatory), Application (Oncotherapy, Diabetes, Analgesia, Nutrition, and Others), End-User (Hospitals, Ambulatory Surgical Centers, Homecare Settings, and Others), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of chronic diseases and increasing technological advancements
The global drug infusion systems market was valued at USD 11.73 billion in 2023, growing at a CAGR of 8.85% during the forecast period from 2024 to 2030 to reach USD 19.45 billion by 2030. The demand for drug infusion systems is primarily being boosted by the rising prevalence of chronic diseases such as cancer, diabetes, and others coupled with the increasing geriatric population and technological advancements in product development among others.
Drug Infusion Systems Market Dynamics:
The drug infusion systems market is slated to register significant growth in the forecast period due to the rising prevalence of various cancers and other chronic diseases. For instance, according to the data cited by the World Health Organization (WHO) 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.
As per the statistics published by the International Diabetes Federation (IDF) (2023), worldwide 537 million adults were living with diabetes in 2021. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.
The above-mentioned facts are examples of cancers and chronic diseases that are witnessing a rapid increase across the globe. Chronic diseases often impact individuals for the course of their lifetime and require therapeutic interventions for prolonged periods. To achieve that, drug infusion systems are used. Drug infusion systems are medical devices that are employed in the delivery of drugs such as antibiotics, pain relievers, hormones, and chemotherapy drugs as well as nutrients to the patients. These systems are available in various configurations such as stationary as well ambulatory ones. These devices offer a safe and accurate mode of drug delivery without the constant need for verifying the amount of dose being administered.
Moreover, technological advancements have led to the development of programmable drug infusion systems where flow rates and alarms among other features are being offered for easy tracking of the administered doses. For instance, the Space ecosystem by B. Braun Melsugen AG is an integrated infusion system that comes with the OnlineSuiteplus. This integrated system offers features such as connectivity and data management and standardized interoperability, outstanding therapy, and cloud-based applications among other features.
However, product recalls as well as technical problems associated with infusion systems such as disconnection, and issues in calibration may prove to be certain restraints to the drug infusion systems market growth.
Drug Infusion Systems Market Segment Analysis:
Drug Infusion Systems Market by Product Type (Syringe Infusion Systems, Elastomeric Infusion Systems, Large-Volume Infusion Systems, Enteral Infusion Systems, Patient-Controlled Analgesic Infusion Systems, Insulin Pumps, and Others), Product Placement (External and Implantable), Portability (Fixed and Ambulatory), Application (Oncotherapy, Diabetes, Analgesia, Nutrition, and Others), End-User (Hospitals, Ambulatory Surgical Centers, Homecare Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment in the drug infusion systems market, syringe-based infusion systems are estimated to account for a significant share of the market.
This is due to their simple product design and wide applicability.
Syringe pumps are extensively used in clinical settings as the majority of the medications are available in syringe forms. Therefore, a syringe is fitted into the system and programmed for the delivery of the drug as per the requirement.
These systems are useful in the delivery of low medication volumes for medication required in small quantities.
Syringe infusion systems are particularly ideal for dose administration in younger patients such as babies, neonates, and young children.
Hence, owing to the advantages offered by syringe infusion systems, their demand will increase during the forecast period.
North America is expected to dominate the Overall Drug Infusion Systems Market:
Among all the regions, North America is expected to account for the largest share of the drug infusion systems market. The growing prevalence of chronic diseases such as chronic low back pain, diabetes, and cancers, a well-established healthcare system along with the presence of major market players in the region are predicted to be the major influencing factors in driving the overall growth of the drug infusion systems market over the forecast period.
As per the facts provided by the Centers for Disease Prevention and Control (CDC), according to the National Health Survey 2019, about 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited work or life activities (considered as high impact chronic pain) in 2019. It was observed in the survey that high-impact chronic pain and chronic pain affected people over 65 and above more commonly and worsen with age.
As per the figures mentioned by the American Cancer Society 2021, it was estimated that 1.9 million new cancer cases have been diagnosed in the United States in 2021. Also, according to the data provided by the CDC in 2021, around 1,752,735 new cases of cancer were reported in the US in 2019. As per Globocan 2021 data, there were around 61,152 new cases of leukemia recorded in 2020 in the United States.
As these indications require long-term disease management, drug infusion systems prove to be extremely useful devices in the administration of pain management therapies as well as chemotherapy.
Moreover, the US houses a large number of key players in the market which can be attributed to the conducive product development environment along with better opportunities in terms of market access to the end users.
In June 2019, Ivenix Inc received 510k approval from the US Food and Drug Administration for their Ivenix Infusion System, which was the first and only large-volume pump and infusion system designed with the new FDA infusion guidelines, first adopted in 2014.
Therefore, with the presence of a large patient pool, along with an active regulatory body as well as active key market players in the country and the region, the market outlook for drug infusion systems is expected to be promising in the US and North America.
Drug Infusion Systems Market Key Players:
Some of the key market players operating in the drug infusion systems market include B. Braun Melsungen AG, Medtronic, BD, PROMECON GmbH, arcomed ag, Fresenius Kabi AG, Microport Scientific Corporation, Teleflex Incorporated., Smiths Medical, Baxter, Ivenix Inc, Terumo Corporation, Insulet Corporation., FLOWONIX MEDICAL INC, Intera Oncology and others.
Recent Developmental Activities in Drug Infusion Systems Market:
In September 2020, B. Braun Melsungen received 510k clearance from the US FDA for their SpaceStation MRI to allow Space® infusion pumps. These systems are meant for the delivery of medications to patients within the MRI suites.
In May 2020, Baxter received the CE mark approval and regulatory approval from Australia's Therapeutic Goods Administration (TGA) for their Evo IQ Syringe Infusion System. The system can be employed in the delivery of small volumes of fluids and other medications to patients in a controlled manner.
Key Takeaways from the Drug Infusion Systems Market Report Study
Market size analysis for current drug infusion systems market size (2023), and market forecast for 5 years (2024-2030)
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global drug infusion systems market.
Various opportunities available for the other competitor in the drug infusion systems market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current drug infusion systems market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for drug infusion systems market growth in the coming future?
Target Audience who can be benefited from this Drug Infusion Systems Market Report Study
Drug infusion systems products providers
Research organizations and consulting companies
Drug infusion systems-related organization, association, forum, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in drug infusion systems
Various End-Users who want to know more about the drug infusion systems market and the latest technological developments in the drug infusion systems market.
Frequently Asked Questions for Drug Infusion Systems Market:
Drug Infusion Systems are medical devices that help in the administration of drugs such as pain relievers, antibiotics, and chemotherapy drugs to patients. These systems are also used in the administration of nutrients as well.
The global drug infusion systems market was valued at USD 11.73 billion in 2023, growing at a CAGR of 8.85% during the forecast period from 2024 to 2030 to reach USD 19.45 billion by 2030.
Some of the factors positively influencing the drug infusion systems market are the increasing prevalence of chronic diseases, and various cancers, the rising geriatric population, and technological advancement in product development.
Some of the prominent market players operating in the drug infusion systems market include B. Braun Melsungen AG, Medtronic, BD, PROMECON GmbH, arcomed ag, Fresenius Kabi AG, Microport Scientific Corporation, Teleflex Incorporated., Smiths Medical, Baxter, Ivenix Inc, Terumo Corporation, Insulet Corporation., FLOWONIX MEDICAL INC, Intera Oncology and others.
North America is expected to account for the highest revenue share in the drug infusion systems market during the forecast period. Factors such as access to better healthcare, a rising number of patients suffering from chronic diseases such as diabetes, and chronic back pain, and increasing product launches in the region are expected to drive the growth of the North American Drug Infusion Systems market.